Nature Reviews Drug Discovery 17, 81–85 (2018)
Semaglutide is the sixth GLP1 agonist to receive FDA approval, not the fifth as originally noted. This correction has been made in the print and online versions.
Additional information
The online version of the original article can be found at https://doi.org/10.1038/nrd.2018.4
Rights and permissions
About this article
Cite this article
Mullard, A. Erratum: 2017 FDA drug approvals. Nat Rev Drug Discov 17, 150 (2018). https://doi.org/10.1038/nrd.2018.18
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrd.2018.18
This article is cited by
-
Defining a metabolic landscape of tumours: genome meets metabolism
British Journal of Cancer (2020)
